Younger severe asthma patients with interleukin 4 (CC variant) and dupilumab treatment are more likely to achieve clinical remission

Table 2 Comparison between the effect of different Naïve biologic used in treatment of patients with severe asthma

Factors	Omalizumab (n = 42)		Dupilumab (n = 29)		p
Factors	Median	IQR	Median	IQR	p
ACT	22	(20–25)	23	(21–25)	0.11
ACQ-6	0.8	(0.33–1.7)	0.6	(0.1-1)	0.01^†††
FeNO	19	(14–27)	20	(16.5–26)	0.22
IgE	458.5	(235.5-953.5)	447	(223–866)	0.11
BEC	200	(145–360)	440	(195–930)	0.001^†††
FEV1% predicted	76.3	(60.45–87.5)	81	(73–90)	0.33
FVC % predicted	77	(63.5–88.5)	78.5	(75.25–90.5)	0.52
FEV1:FVC % predicted	77.8	(76.6–79.3)	79.2	(76.9–80)	0.16

The numerical data presented as median and inter quartile range, N: number, IQR: interquartile range, ACT: asthma control test, ACQ-6: Asthma control quality of life, BEC: Blood eosinophil count, FeNO: Fractional exhaled nitric oxide, FEV1: Forced expiratory volume in one second, FVC: Forced vital capacity. †††: The test of significant: Kruskal Wallis test, p ≤ 0.05 considered significant

ISSN: 1471-2466